|
|
Volumn 97, Issue 2, 2005, Pages 86-87
|
|
Anastrozole data show continued delay in relapse, but no clear survival advantage
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
AROMATASE INHIBITOR;
BISPHOSPHONIC ACID DERIVATIVE;
ESTROGEN RECEPTOR;
EXEMESTANE;
LETROZOLE;
PLACEBO;
TAMOXIFEN;
TAXANE DERIVATIVE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
NITRILE;
TRIAZOLE DERIVATIVE;
ARTHRALGIA;
BRAIN ISCHEMIA;
BREAST CANCER;
BUDGET;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DATA ANALYSIS;
DRUG APPROVAL;
DRUG CHOICE;
DRUG COST;
DRUG EFFICACY;
EARLY CANCER;
ENDOMETRIUM CANCER;
HORMONE RESPONSE;
HOT FLUSH;
HUMAN;
MEDICAL DECISION MAKING;
MEDICAL EXPERT;
MONOTHERAPY;
NOTE;
POSTMENOPAUSE;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY OF LIFE;
RECURRENCE RISK;
RISK BENEFIT ANALYSIS;
STATISTICAL SIGNIFICANCE;
THROMBOEMBOLISM;
VAGINA BLEEDING;
VAGINA DISCHARGE;
VERTEBRA FRACTURE;
ARTICLE;
BREAST TUMOR;
CONTROLLED CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
ECONOMICS;
FEMALE;
NEOPLASM;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AROMATASE INHIBITORS;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
DISEASE-FREE SURVIVAL;
DRUG COSTS;
FEMALE;
GREAT BRITAIN;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASMS, HORMONE-DEPENDENT;
NITRILES;
RANDOMIZED CONTROLLED TRIALS;
SURVIVAL ANALYSIS;
TAMOXIFEN;
TREATMENT OUTCOME;
TRIAZOLES;
|
|
EID: 13744254563
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/97.2.86 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|